The Association of the British Pharmaceutical Industry (ABPI) has welcomed the news that a major pharmaceutical company is to open a tuberculosis research centre in India.
The aim of the centre is to produce new treatments for TB that can be provided "The pharmaceutical industry has consistently provided essential medicines for diseases of the developing world, and this is the latest example of the industry's determined commitment to continue this activity," said Dr Trevor Jones, Director General of the ABPI.
"It is easy for commentators to use the industry as a target for their anger and frustration at the appalling healthcare problems facing men, women and children in the world's poorer nations, but it is also easier to overlook the huge efforts and resources that we are committing to projects such as this initiative and those related to HIV/AIDS, malaria and leprosy."
But solutions to the world's healthcare problems cannot be solved purely by the pharmaceutical industry operating alone. "It is essential that the others involved should also play their part - particularly governments in the rich world, providing the necessary support and resource; and governments of the developing world, making health a priority. International organisations, non-governmental organisations, and global charities must also be committed to this joint activity," said Dr Jones.
"This initiative in India is just one example of our commitment - it would be good to see a similar commitment from other stakeholders involved in solving the problems of providing essential healthcare services to people with the greatest need for suitable solutions for their future survival."
For further information, please contact: ABPI Press Office 020 7747 1410